<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01218542</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00045035</org_study_id>
    <secondary_id>WCI1784-10</secondary_id>
    <nct_id>NCT01218542</nct_id>
  </id_info>
  <brief_title>Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc</brief_title>
  <official_title>Whole Brain Radiation Therapy With Simultaneous Boost to Gross Metastatic Tumor Volume Using Volumetric Modulated Arc Therapy (RapidArc)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brain metastases are the most common adult intracranial tumor, occurring in approximately 10%&#xD;
      to 30% of adult cancer patients, and represent an important cause of morbidity and mortality.&#xD;
      The most widely used treatment for patients with multiple brain metastases is whole brain&#xD;
      radiation therapy (WBRT). The use of WBRT after resection or stereotactic radiosurgery (SRS)&#xD;
      has been proven to be effective in terms of improving local control of brain metastases.&#xD;
&#xD;
      RapidArc (RA) (Varian Medical Systems, Palo Alto, CA) is a new method of delivering radiation&#xD;
      that uses &quot;arcs&quot; to deliver highly conformal intensity modulated three dimensional dose&#xD;
      distributions. The purpose of this investigation is to evaluate an alternative strategy for&#xD;
      giving WBRT with highly focal boost to gross visible lesions in patients with brain&#xD;
      metastasis.&#xD;
&#xD;
      Given the limitations of the SRS boost technique, the purpose of our investigation is to&#xD;
      evaluate an alternative strategy for giving WBRT with highly focal boost to gross visible&#xD;
      lesions in patients with brain metastasis. In this study, we plan to assess the tolerability&#xD;
      of using volumetric modulated arc therapy (RapidArc) on patients with brain metastasis to&#xD;
      simultaneously treat the entire brain with a concomitant focal boost to grossly identified&#xD;
      lesions on MRI scan to try to improve local control and reduce neurocognitive toxicities.&#xD;
&#xD;
      This previous version of this study was a phase I dose escalation trial giving 25 Gy in 10&#xD;
      fractions to the whole brain with simultaneous infield boost (SIB) to a total of 45 Gy in 10&#xD;
      fractions to gross brain metastatic disease. Prior to this, patients were enrolled onto one&#xD;
      of two cohorts with whole brain dose of 30 Gy in 10 fractions with SIB to total of 45 Gy in&#xD;
      10 fractions to gross brain metastatic disease or whole brain dose of 37.5 Gy in 15 fractions&#xD;
      with SIB to total of 52.5 Gy in 15 fractions to gross brain metastatic disease. A total of 12&#xD;
      patients have been previously enrolled on this trial. No patients have experienced a dose&#xD;
      limiting toxicity (grade 3 or above) at least possibly due to study therapy. Also, no&#xD;
      patients experienced local brain failure/progression at a site of treated metastatic brain&#xD;
      disease. Based on this, we no longer feel that dose escalation to the gross brain disease is&#xD;
      warranted and would proceed with a single arm pilot study treating patients with 25 Gy in 10&#xD;
      fractions to the whole brain with simultaneous infield boost (SIB) to a total of 45 Gy in 10&#xD;
      fractions to gross brain metastatic disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 22, 2010</start_date>
  <completion_date type="Actual">June 3, 2020</completion_date>
  <primary_completion_date type="Actual">June 3, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients</measure>
    <time_frame>Locoregional control at 1 year</time_frame>
    <description>The cumulative incidences of recurrence locally and in the whole brain were reported at the patient level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain Progression-free Survival</measure>
    <time_frame>11 months median follow up period.</time_frame>
    <description>Defined as period of time from study entry to to death from any cause or brain tumor recurrence or progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>11 months median follow up period.</time_frame>
    <description>Defined time from study entry to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Effects</measure>
    <time_frame>11 months median follow up period.</time_frame>
    <description>Neurological test score were assessed using the Hopkins Verbal Learning Test-Revised (HVLT).&#xD;
In the HVLT 12 words are read and the participant is asked to recall them, this is completed 3 times.&#xD;
Total words recalled are summed to give a score for Total Recall (0-36, higher scores demonstrated better recall).&#xD;
Delayed recall is conducted 20-25 minutes later on the same list of 12 words (scored 0-12 with higher scores demonstrating better recall).&#xD;
Retention is calculated as the percent of words recalled (scored 0-100, higher scores representing better recall).&#xD;
Recognition Discrimination is tested by a series of yes/no responses from the participant identifying 12 target words from a list of 24 and calculated by the number of true positives minus the number of true negatives with higher scores indicating a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by the FACT-Br Subscales</measure>
    <time_frame>11 month median follow up</time_frame>
    <description>The Functional Assessment of Cancer Therapy-Brain (FACT-Br) were summed to create the FACT brain trial outcome index (FACT-BR TOI), FACT general (FACT-G), and FACT brain total (FACT-BR Total).&#xD;
Three FACT scales were calculated. The higher the value the better the score, i.e., the better the quality of life perceived by patient.&#xD;
FACT BR TOTAL (FACT-G + BrCS, possible range 0 - 200) FACT-BR TOI (Trial Outcome Index = Physical Well Being _ Functional Well Being +BrCS, possible range 0 - 148) FACT-G (Fact General, possible range 0 - 108)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Volumetric modulated arc therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm pilot study treating patients with 25 Gy in 10 fractions to the whole brain with simultaneous infield boost (SIB) to a total of 45 Gy in 10 fractions to gross brain metastatic disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Volumetric modulated arc therapy</intervention_name>
    <description>Using volumetric modulated arc therapy to give simultaneous infield boost to gross metastatic brain lesions during whole brain radiation therapy.</description>
    <arm_group_label>Volumetric modulated arc therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologic proven diagnosis of solid tumor malignancy.&#xD;
&#xD;
          -  Age ≥ 18.&#xD;
&#xD;
          -  KPS ≥ 70.&#xD;
&#xD;
          -  Mini Mental Status Exam (MMSE) ≥ 18 prior to study entry.&#xD;
&#xD;
          -  RPA class I (KPS ≥ 70, primary cancer controlled, age &lt; 65, metastases in brain only)&#xD;
             or class II (lack of one or more of class I criteria).&#xD;
&#xD;
          -  One to ten brain metastatic lesions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous whole brain radiation therapy.&#xD;
&#xD;
          -  Previous radiosurgery to any currently progressive gross metastatic disease.&#xD;
&#xD;
          -  Previous radiosurgery to any intracranial site within the prior 6 weeks.&#xD;
&#xD;
          -  Recursive partitioning analysis (RPA) class III (KPS &lt; 70).&#xD;
&#xD;
          -  Radiosensitive (eg. small cell lung carcinomas, germ cell tumors, leukemias, or&#xD;
             lymphomas) or unknown tumor histologies.&#xD;
&#xD;
          -  Concurrent chemotherapy (no chemotherapy starting 14 days before start of radiation).&#xD;
&#xD;
          -  Evidence of leptomeningeal disease by MRI and/or cerebrospinal fluid (CSF) cytology.&#xD;
&#xD;
          -  Current pregnancy.&#xD;
&#xD;
          -  No metastases to brain stem, midbrain, pons, or medulla or within 7 mm of the optic&#xD;
             apparatus (optic nerves and chiasm).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui-Kuo Shu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zimm S, Wampler GL, Stablein D, Hazra T, Young HF. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer. 1981 Jul 15;48(2):384-94.</citation>
    <PMID>7237407</PMID>
  </reference>
  <reference>
    <citation>Sundström JT, Minn H, Lertola KK, Nordman E. Prognosis of patients treated for intracranial metastases with whole-brain irradiation. Ann Med. 1998 Jun;30(3):296-9.</citation>
    <PMID>9677016</PMID>
  </reference>
  <reference>
    <citation>CHAO JH, PHILLIPS R, NICKSON JJ. Roentgen-ray therapy of cerebral metastases. Cancer. 1954 Jul;7(4):682-9.</citation>
    <PMID>13172684</PMID>
  </reference>
  <reference>
    <citation>Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51.</citation>
    <PMID>9128946</PMID>
  </reference>
  <reference>
    <citation>Patchell RA, Regine WF. The rationale for adjuvant whole brain radiation therapy with radiosurgery in the treatment of single brain metastases. Technol Cancer Res Treat. 2003 Apr;2(2):111-5. Review.</citation>
    <PMID>12680791</PMID>
  </reference>
  <reference>
    <citation>Arbit E, Wroński M, Burt M, Galicich JH. The treatment of patients with recurrent brain metastases. A retrospective analysis of 109 patients with nonsmall cell lung cancer. Cancer. 1995 Sep 1;76(5):765-73.</citation>
    <PMID>8625178</PMID>
  </reference>
  <reference>
    <citation>Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004 May 22;363(9422):1665-72.</citation>
    <PMID>15158627</PMID>
  </reference>
  <reference>
    <citation>Lagerwaard FJ, van der Hoorn EA, Verbakel WF, Haasbeek CJ, Slotman BJ, Senan S. Whole-brain radiotherapy with simultaneous integrated boost to multiple brain metastases using volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):253-9. doi: 10.1016/j.ijrobp.2009.03.029. Epub 2009 Jul 4.</citation>
    <PMID>19577856</PMID>
  </reference>
  <reference>
    <citation>Bauman G, Yartsev S, Fisher B, Kron T, Laperriere N, Heydarian M, VanDyk J. Simultaneous infield boost with helical tomotherapy for patients with 1 to 3 brain metastases. Am J Clin Oncol. 2007 Feb;30(1):38-44.</citation>
    <PMID>17278893</PMID>
  </reference>
  <results_reference>
    <citation>Zhong J, Waldman AD, Kandula S, Eaton BR, Prabhu RS, Huff SB, Shu HG. Outcomes of whole-brain radiation with simultaneous in-field boost (SIB) for the treatment of brain metastases. J Neurooncol. 2020 Mar;147(1):117-123. doi: 10.1007/s11060-020-03405-y. Epub 2020 Jan 22.</citation>
    <PMID>31970594</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 30, 2010</study_first_submitted>
  <study_first_submitted_qc>October 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2010</study_first_posted>
  <results_first_submitted>June 26, 2020</results_first_submitted>
  <results_first_submitted_qc>June 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 29, 2021</results_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Hui-Kuo Shu, MD, PhD</investigator_full_name>
    <investigator_title>MD, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Secondary brain malignancies</keyword>
  <keyword>RapidArc</keyword>
  <keyword>Volumetric modulated arc therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 9, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT01218542/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited at Winship Cancer Institute of Emory University from September 2010 to September 2015.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Volumetric Modulated Arc Therapy</title>
          <description>Single arm pilot study treating patients with 25 Gy in 10 fractions to the whole brain with simultaneous infield boost (SIB) to a total of 45 Gy in 10 fractions to gross brain metastatic disease.&#xD;
Volumetric modulated arc therapy: Using volumetric modulated arc therapy to give simultaneous infield boost to gross metastatic brain lesions during whole brain radiation therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Volumetric Modulated Arc Therapy</title>
          <description>Single arm pilot study treating patients with 25 Gy in 10 fractions to the whole brain with simultaneous infield boost (SIB) to a total of 45 Gy in 10 fractions to gross brain metastatic disease.&#xD;
Volumetric modulated arc therapy: Using volumetric modulated arc therapy to give simultaneous infield boost to gross metastatic brain lesions during whole brain radiation therapy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients</title>
        <description>The cumulative incidences of recurrence locally and in the whole brain were reported at the patient level.</description>
        <time_frame>Locoregional control at 1 year</time_frame>
        <population>Feasibility by our criteria was met for all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Volumetric Modulated Arc Therapy</title>
            <description>Single arm pilot study treating patients with 25 Gy in 10 fractions to the whole brain with simultaneous infield boost (SIB) to a total of 45 Gy in 10 fractions to gross brain metastatic disease.&#xD;
Volumetric modulated arc therapy: Using volumetric modulated arc therapy to give simultaneous infield boost to gross metastatic brain lesions during whole brain radiation therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients</title>
          <description>The cumulative incidences of recurrence locally and in the whole brain were reported at the patient level.</description>
          <population>Feasibility by our criteria was met for all participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-year Local Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lesion Level Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-year Regional Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intracranial Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distant Intracranial Recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brain Progression-free Survival</title>
        <description>Defined as period of time from study entry to to death from any cause or brain tumor recurrence or progression.</description>
        <time_frame>11 months median follow up period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Volumetric Modulated Arc Therapy</title>
            <description>Single arm pilot study treating patients with 25 Gy in 10 fractions to the whole brain with simultaneous infield boost (SIB) to a total of 45 Gy in 10 fractions to gross brain metastatic disease.&#xD;
Volumetric modulated arc therapy: Using volumetric modulated arc therapy to give simultaneous infield boost to gross metastatic brain lesions during whole brain radiation therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Brain Progression-free Survival</title>
          <description>Defined as period of time from study entry to to death from any cause or brain tumor recurrence or progression.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="2.9" upper_limit="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Defined time from study entry to death from any cause.</description>
        <time_frame>11 months median follow up period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Volumetric Modulated Arc Therapy</title>
            <description>The 2-year neurocognitive effect was not collected. We collected and reported neurocognitive data up to 6 months after treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Defined time from study entry to death from any cause.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" lower_limit="4.1" upper_limit="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Effects</title>
        <description>Neurological test score were assessed using the Hopkins Verbal Learning Test-Revised (HVLT).&#xD;
In the HVLT 12 words are read and the participant is asked to recall them, this is completed 3 times.&#xD;
Total words recalled are summed to give a score for Total Recall (0-36, higher scores demonstrated better recall).&#xD;
Delayed recall is conducted 20-25 minutes later on the same list of 12 words (scored 0-12 with higher scores demonstrating better recall).&#xD;
Retention is calculated as the percent of words recalled (scored 0-100, higher scores representing better recall).&#xD;
Recognition Discrimination is tested by a series of yes/no responses from the participant identifying 12 target words from a list of 24 and calculated by the number of true positives minus the number of true negatives with higher scores indicating a better outcome.</description>
        <time_frame>11 months median follow up period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Volumetric Modulated Arc Therapy</title>
            <description>Single arm pilot study treating patients with 25 Gy in 10 fractions to the whole brain with simultaneous infield boost (SIB) to a total of 45 Gy in 10 fractions to gross brain metastatic disease.&#xD;
Volumetric modulated arc therapy: Using volumetric modulated arc therapy to give simultaneous infield boost to gross metastatic brain lesions during whole brain radiation therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Effects</title>
          <description>Neurological test score were assessed using the Hopkins Verbal Learning Test-Revised (HVLT).&#xD;
In the HVLT 12 words are read and the participant is asked to recall them, this is completed 3 times.&#xD;
Total words recalled are summed to give a score for Total Recall (0-36, higher scores demonstrated better recall).&#xD;
Delayed recall is conducted 20-25 minutes later on the same list of 12 words (scored 0-12 with higher scores demonstrating better recall).&#xD;
Retention is calculated as the percent of words recalled (scored 0-100, higher scores representing better recall).&#xD;
Recognition Discrimination is tested by a series of yes/no responses from the participant identifying 12 target words from a list of 24 and calculated by the number of true positives minus the number of true negatives with higher scores indicating a better outcome.</description>
          <units>fraction of post-tx over pre-tx scores</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.73" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delayed Recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" lower_limit="0.90" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.72" upper_limit="1.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recognition Discrimination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" lower_limit="0.77" upper_limit="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by the FACT-Br Subscales</title>
        <description>The Functional Assessment of Cancer Therapy-Brain (FACT-Br) were summed to create the FACT brain trial outcome index (FACT-BR TOI), FACT general (FACT-G), and FACT brain total (FACT-BR Total).&#xD;
Three FACT scales were calculated. The higher the value the better the score, i.e., the better the quality of life perceived by patient.&#xD;
FACT BR TOTAL (FACT-G + BrCS, possible range 0 - 200) FACT-BR TOI (Trial Outcome Index = Physical Well Being _ Functional Well Being +BrCS, possible range 0 - 148) FACT-G (Fact General, possible range 0 - 108)</description>
        <time_frame>11 month median follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Volumetric Modulated Arc Therapy</title>
            <description>Single arm pilot study treating patients with 25 Gy in 10 fractions to the whole brain with simultaneous infield boost (SIB) to a total of 45 Gy in 10 fractions to gross brain metastatic disease.&#xD;
Volumetric modulated arc therapy: Using volumetric modulated arc therapy to give simultaneous infield boost to gross metastatic brain lesions during whole brain radiation therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life as Measured by the FACT-Br Subscales</title>
          <description>The Functional Assessment of Cancer Therapy-Brain (FACT-Br) were summed to create the FACT brain trial outcome index (FACT-BR TOI), FACT general (FACT-G), and FACT brain total (FACT-BR Total).&#xD;
Three FACT scales were calculated. The higher the value the better the score, i.e., the better the quality of life perceived by patient.&#xD;
FACT BR TOTAL (FACT-G + BrCS, possible range 0 - 200) FACT-BR TOI (Trial Outcome Index = Physical Well Being _ Functional Well Being +BrCS, possible range 0 - 148) FACT-G (Fact General, possible range 0 - 108)</description>
          <units>fraction of post-tx over pre-tx scores</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FACT-BR Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.93" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACT-BR TOI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" lower_limit="0.87" upper_limit="1.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACT-G</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" lower_limit="0.73" upper_limit="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected thorughout the study assessed up to 2 year follow-up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Volumetric Modulated Arc Therapy</title>
          <description>Single arm pilot study treating patients with 25 Gy in 10 fractions to the whole brain with simultaneous infield boost (SIB) to a total of 45 Gy in 10 fractions to gross brain metastatic disease.&#xD;
Volumetric modulated arc therapy: Using volumetric modulated arc therapy to give simultaneous infield boost to gross metastatic brain lesions during whole brain radiation therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Radiation Necrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Hui-Kuo Shu</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-2161</phone>
      <email>hgshu@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

